Lynparza (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer

KENILWORTH, N.J.--(BUSINESS WIRE)--May 8, 2020 -- AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Lynparza in combination with...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news